	US 12,234,233 B2
	Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof
Zhonghui Wan, Jiangsu (CN); and Lin Li, Jiangsu (CN)
Assigned to TRANSTHERA SCIENCES (NANJING), INC., Jiangsu (CN)
Appl. No. 17/439,591
Filed by TRANSTHERA SCIENCES (NANJING), INC., Jiangsu (CN)
PCT Filed Mar. 13, 2020, PCT No. PCT/CN2020/079337 § 371(c)(1), (2) Date Sep. 15, 2021, PCT Pub. No. WO2020/187165, PCT Pub. Date Sep. 24, 2020.
Claims priority of application No. 201910199611.6 (CN), filed on Mar. 15, 2019; application No. 201910228418.0 (CN), filed on Mar. 25, 2019; and application No. 201910789020.4 (CN), filed on Aug. 26, 2019.
Prior Publication US 2022/0194934 A1, Jun. 23, 2022 Prior Publication US 2023/0125064 A2, Apr. 20, 2023
Int. Cl. C07D 471/04 (2006.01)

CPC C07D 471/04 (2013.01) [C07B 2200/13 (2013.01)]

19 Claims

1. A crystal form I of a compound as shown in formula (I), 6-ethyl-4-(4-methoxy-4-methylpiperidin-1-yl)-2-oxo-1,2-dihydro-1,7-diazanaphthalene-3-carbonitrile, wherein the crystal form has an X-ray powder diffraction pattern comprising characteristic peaks at 7.3±0.2°, 13.6±0.2°, 14.5±0.2°, 18.0±0.2°, 19.1±0.2°, 22.0±0.2° and 23.4±0.2° 2θ, by using Cu-Kα radiation,